Biogen Company Profile
✉ Email this page to a colleague
What is the competitive landscape for BIOGEN, and what generic alternatives to BIOGEN drugs are available?
BIOGEN has five approved drugs.
There are twenty-eight US patents protecting BIOGEN drugs.
There are three hundred and forty-two patent family members on BIOGEN drugs in forty-three countries and seventy-one supplementary protection certificates in eighteen countries.
Summary for Biogen
| International Patents: | 342 |
| US Patents: | 28 |
| Tradenames: | 5 |
| Ingredients: | 5 |
| NDAs: | 5 |
| Patent Litigation for Biogen: | See patent lawsuits for Biogen |
| PTAB Cases with Biogen as patent owner: | See PTAB cases with Biogen as patent owner |
Drugs and US Patents for Biogen
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biogen Inc | TECFIDERA | dimethyl fumarate | CAPSULE, DELAYED RELEASE;ORAL | 204063-001 | Mar 27, 2013 | AB | RX | Yes | No | 11,007,166 | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Biogen Inc | TECFIDERA | dimethyl fumarate | CAPSULE, DELAYED RELEASE;ORAL | 204063-002 | Mar 27, 2013 | AB | RX | Yes | Yes | 10,391,160 | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Biogen Inc | ZURZUVAE | zuranolone | CAPSULE;ORAL | 217369-003 | Oct 31, 2023 | RX | Yes | Yes | 11,884,696 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Biogen
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Biogen Idec | SPINRAZA | nusinersen sodium | SOLUTION;INTRATHECAL | 209531-001 | Dec 23, 2016 | 7,101,993 | ⤷ Try a Trial |
| Biogen Idec | SPINRAZA | nusinersen sodium | SOLUTION;INTRATHECAL | 209531-001 | Dec 23, 2016 | 6,166,197 | ⤷ Try a Trial |
| Biogen Inc | TECFIDERA | dimethyl fumarate | CAPSULE, DELAYED RELEASE;ORAL | 204063-002 | Mar 27, 2013 | 8,524,773 | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for BIOGEN drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Delayed-releaseCapsules | 120 mg and 240 mg | ➤ Subscribe | 2017-03-27 |
International Patents for Biogen Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| European Patent Office | 3449926 | ⤷ Try a Trial |
| China | 110088091 | ⤷ Try a Trial |
| Spain | 2709434 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Biogen Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2548560 | C20170038 00228 | Estonia | ⤷ Try a Trial | PRODUCT NAME: NUSINERSEEN;REG NO/DATE: EU/1/17/1188 01.06.2017 |
| 1910395 | 2017/051 | Ireland | ⤷ Try a Trial | PRODUCT NAME: NUSINERSEN OR SALTS THEREOF; REGISTRATION NO/DATE: EU/1/17/1188 20170530 |
| 2970101 | 122022000014 | Germany | ⤷ Try a Trial | PRODUCT NAME: DIROXIMELFUMARAT; NAT. REGISTRATION NO/DATE: EU/1/21/1585 20211115; FIRST REGISTRATION: SCHWEIZ 68066 20210920 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
